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companies. METHODS: We identified branded antidepressant and antipsychotic
launches between 2003 and 2010. Market authorisation dates and P&R dates were
sourced from national databases and launch dates were determined using IMS
MIDAS data. The average time between market authorisation, P&R and launch was
then calculated for fifteen European countries. RESULTS: In most countries the
identified products were not launched until P&R was secured, making it a signifi-
cant barrier to patient access. The average time taken to achieve P&R was approx-
imately 310 days, with significant variation between countries. This delay was
frequently longer than the average P&R delay seen across all therapy areas. On
average only the UK, Germany and Denmark achieved P&R within Transparency
Directive guidelines. Significant delays were seen in Portugal and France, taking on
average 550 and 610 days respectively to gain P&R. CONCLUSIONS: In addition to
known development challenges for CNS products, manufacturers experience
greater delays in securing P&R in Europe, denying patients timely access to these
drugs. Few countries comply with the current Transparency Directive[2], and if
proposed changes are implemented to reduce the delay to 120 days, even fewer will
be compliant. P&R is an additional hurdle to access that particularly impacts CNS
drugs, and stronger efforts to reduce these delays are needed.
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OBJECTIVES: Recently, there is growing evidence of inappropriate variation in use
of certain medicines. In Serbia the consumption of pentoxifylline, dihydroergotox-
ine, nicergoline, deproteinized calf blood extract (DCBE) and cinnarizine, drugs
with uncertain clinical benefit (UCB drugs), with clinical trials with little evidence
suggesting their clinical benefit, is unusually high. The aim of this study was to
analyze the consumption of UCB drugs in second largest city in Serbia – Novi Sad,
in 1984 and 2008., to compare with those in entire Serbia, Denmark and Norway,
and to examine the potential impact on population budget. METHODS: The study
included data on consumption of these medicines in 1984. and 2008., in Novi Sad.
Data were obtained from all state-owned and private pharmacies on the territory of
Novi Sad. The number of (DDD/1000 inh/day) was calculated using ATC/DDD
methodology. RESULTS: Total consumption of analyzed drugs with uncertain clin-
ical benefit in Novi Sad has surprisingly increased in 2008 (12,59DDD/TID) in com-
parison to 1984 (7.37DDD/TID). Also, their total consumption in entire Serbia in
2008. was higher than in Novi Sad (16,72DDD/TID) and even several dozens of times
higher than in Denmark and Norway (0.2DDD/TID). The money which population
spent for UCB drugs yearly was more than 90 Mill EU in Serbia Although different
administrative and educational approaches were applied in Serbia, their use not
only did not decrease, but has significantly increased throughout years.
CONCLUSIONS: These results suggest the need for putting greater efforts into ed-
ucation of general population who buys the UCB medicines in high amounts on
their own accord. The work is part of SerbianSP No41012.
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OBJECTIVES: A reimbursement prediction model was previously developed based
on a dataset of submissions to the Scottish Medicines Consortium (SMC) between
2008 and 2010. The aim was to update and re-analyze the dataset, and to test
internal and external validity of the prediction model on submissions from 2011
and 2012. METHODS: A database of submissions between January 2005 and March
2012 was created. Data of 405 applications were collected, including information on
the reimbursement decision (yes/no), clinical data and indicators of the health
economic model quality supporting the submission. The impact of these variables
was estimated with univariate and multivariate logistic regression models. The
multivariate model was identified by a backward selection procedure. Internal
validity was assessed by the area under the receiver operating characteristic (ROC)
curve. External validity was conducted and judged by a classification test to predict
the SMC decision based on 2011-2012 data. RESULTS: Out of 405 applications 226
received positive recommendation (56%) and 131 (58%) of them were reimbursed
with restriction, e.g. limited patient population or restricted time period. Based on
univariate analyses, three factors had the largest significant effect on the reim-
bursement: poor pharmacoeconomic analysis design (OR0.03), high ICER
(OR0.16) and unclear/ inferior efficacy outcomes (OR0.25). The final multivariate
model included the following further factors: antineoplastic-immunomodulating
agent (OR0.47), combination therapy (OR2.00), biological drug (OR0.16), place-
bo-uncontrolled trial (OR0.50), extended indication (OR4.24), innovative drug
(OR2.07). The area under the ROC curve was high; 87.7%. Based on the external
validation, using a model estimated on data until December 2010 and a cut-off
point of 50%, 79.8% of the predicted reimbursement decisions in 2011-2012 were
correctly classified. CONCLUSIONS: The new prediction model demonstrates in-
ternal and external validity for 2011-2012. Therefore, the model could be used as
input when further optimizing the market access strategy for products in clinical
development.
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OBJECTIVES: To compare Dutch and Swedish drug reimbursement decisions and
to investigate the available evidence, used criteria, outcomes and transparency of
the decision-making process.METHODS:We investigated Dutch and Swedish pub-
licly available drug reimbursement dossiers from 2005 until July 2011. Applications
and outcomes were compared and classified into different categories. For dossiers
that included a full pharmacoeconomic evaluation (i.e. cost-effectiveness and/ or
cost-utility analysis) in both countries, we compared in detail how the available
evidence was assessed to appraise societal value. RESULTS: Pharmacoeconomic
evaluations were more often available in Swedish dossiers due to many exemp-
tions in The Netherlands (mainly orphan and HIV drugs). Reimbursement dossiers
only provided a full economic evaluation in both countries for eleven drugs. The
reimbursement decision differed for four drugs, in which relatively more restric-
tions were observed. Although Dutch dossiers provided more details, all dossiers
included information of underlying clinical and economic studies. Comparators
were always reported. Using a similar comparator (8x) resulted in a similar (5x) and
a different (3x) therapeutic value judgement, while a different comparator (3x)
resulted twice in a similar judgement. Swedish ‘yes’ decisions (10x) were judged
cost-effective; ‘no’ decisions (two for one drug) were judged cost-ineffective. Dutch
‘yes’ decisions (9x, including two second decisions) were evaluated sufficiently (3x),
reasonably (1x), moderately (2x), and insufficiently (3x) founded pharmacoeco-
nomic evidence; all ‘no’ decisions (4x) were insufficiently founded. Appraisal ele-
ments were descriptively reported. The (high) severity of the disease was explicitly
mentioned in three overlapping cases. However, the actual influence of disease
severity on the final ‘yes’ decision remained unclear. CONCLUSIONS: Both coun-
tries make their reimbursement reports publicly available. Although the assess-
ment is reasonable transparent, both countries could improve transparency of the
appraisal process by more explicitly showing the actual role of each different (so-
cietal) criterion in drug reimbursement decision making.
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OBJECTIVES: With the current English NHS reforms will the new Clinical Commis-
sioning Groups (CCGs) follow an Italian type regional approach to enable patient
access to innovative and premium priced medicines when implementing patient
access schemes. METHODS: We reviewed the current structures of the first wave
CCGs and their association with the local oncology networks, new commissioning
support bodies and oncology centres to assess the practicality of implementing
current patient access schemes. We also reviewed new schemes approved by the
Italian medicines agency, AIFA, to accelerate reimbursement for new drugs espe-
cially when there is limited availability at launch. RESULTS: It is clear that the
suggested circa 200 proposed CCGs will have limited resources to fund suitable
management structures to run risk share/patient access scheme effectively. Spend
on pharmaceuticals, especially with public and physician demand, for innovative
premium cost cancer treatments, will now be led and influenced by General Prac-
titioners (GPs). The critical question facing family GPs will be how can they address
the funding of these high cost treatments yet still satisfy patient demand. One
approach that could be adopted to a new type of patient access scheme is now
being lead by AIFA who have developed an approach to enhance the reimburse-
ment potential of innovative anti-cancer medicines. CONCLUSIONS: The new
commissioning support bodies recently appointed by the English Department of
Health’s, National Commissioning Board, could easily follow the Italian suggested
approach; to help provide decision-making GPs with a framework to assess new
premium prices medicines, outside of the current support provided by NICE and
the Patient Access Scheme Liaison Unit.
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OBJECTIVES: Coverage decision processes determine the accessibility of health
technologies. Cost-effectiveness considerations have been identified to explain
decision outcomes. Beyond the evidence, outcomes may be influenced by the pro-
cess configurations used by decison makers. The aim of this exploratory study was
to analyse the influences of transparency, stakeholder participation, scientific
rigour of assessment and evidence judgments on decision outcomes in coverage
decision-making. METHODS: Using survey data of 77 decisions from 13 countries,
we examined whether outcomes differ by 14 variables that describe components of
coverage decision-making and the technology considered for coverage. Neglecting
the level of reimbursement, we analysed the likelihood of committees to cover a
technology, i.e. positive (including partial coverage) vs. negative coverage deci-
sions. We performed non-parametric univariate statistical tests and binomial lo-
gistic regression. To identify influences on decision outcomes, we applied a step-
wise variable selection procedure. RESULTS: We identified associations between
the decision outcome and the following variables: the technology is a prescribed
medicine (p0.0097); the health condition is an endocrine, nutritional or metabolic
disease (p0.0311) and the judgment of the evidence after assessment (p0.0001).
The first estimation of the logistic regression model suggested a quasi-complete
separation for those decisions where effectiveness and costs/cost-effectiveness
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